Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice

Antiviral Therapy - Tập 12 Số 3 - Trang 363-370 - 2007
Natalia A. Ilyushina1,2, Erich Hoffmann2, Rachelle Salomon2, Robert G. Webster2,3, Elena A. Govorkova1,2
1D.I. Ivanovsky Institute of Virology, Moscow, Russia
2Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA
3Department of Pathology, University of Tennessee, Memphis, TN, USA

Tóm tắt

Background The clinical management of H5N1 influenza virus infection in humans remains unclear. Combination chemotherapy with drugs that target different viral proteins might be more effective than monotherapy. Methods BALB/c mice were treated by oral gavage for 5 days with amantadine (1.5, 15 or 30 mg/kg/day) and oseltamivir (1 or 10 mg/kg/day) separately or in combination. Mice were challenged 24 h after initiation of treatment with 10 mouse 50% lethal doses of either amantadine-sensitive (having S31 in the M2 protein) or amantadine-resistant (having N31 in the M2 protein) recombinant A/Vietnam/1203/04 (H5N1) virus. Results Combination treatment with amantadine (15 or 30 mg/kg/day) and oseltamivir (10 mg/kg/day) provided greater protection (60% and 90%, respectively) against lethal infection with amantadine-sensitive H5N1 virus than did monotherapy. Moreover, spread of the virus to the brain was prevented by both combination regimens. The efficacy of the drug combinations against amantadine-resistant H5N1 virus was comparable to that of oseltamivir alone. Oseltamivir produced a dose-dependent effect against both recombinant H5N1 viruses ( P<0.05) but did not provide complete protection against lethal infection. Importantly, no mutations in the HA, NA and M2 proteins were detected when the two drugs were used in combination. Conclusions Combination chemotherapy provided a survival advantage over single-agent treatment of mice inoculated with neurotropic H5N1 influenza virus. This strategy might be an option for the control of pandemic influenza viruses that are sensitive to amantadine. Combinations that include other drugs should be explored.

Từ khóa


Tài liệu tham khảo

10.1126/science.1108165

10.7326/0003-4819-143-6-200509200-00011

10.1038/nature02746

10.1378/chest.129.1.156

10.1080/08998280.2006.11928118

World Health Organization, 2006, Weekly Epidemiol Rev, 81, 69

10.1183/09031936.01.00084301

Hayden F.G., 1996, Antiviral Drug Resistance;, 59

10.1016/S0264-410X(03)00075-6

10.2165/00151829-200504020-00004

10.1002/j.1460-2075.1985.tb04038.x

Hayden F.G., 2005, Antivir Ther, 10, 873, 10.1177/135965350501000811

10.1038/363418a0

10.1056/NEJMra052211

10.1016/S0140-6736(05)67338-2

10.1001/jama.295.8.joc60020

10.1016/S0140-6736(04)15595-5

10.1016/j.virol.2005.07.003

10.1056/NEJMp068030

10.1086/504723

10.1086/314515

10.1016/S0166-3542(00)00123-6

10.1128/AAC.45.10.2723-2732.2001

10.1086/432008

10.1128/AAC.48.12.4855-4863.2004

10.1016/j.antiviral.2006.01.012

10.1128/AAC.17.4.642

Hayden F.G., 1986, J Antimicrob Chemother, 18, 77, 10.1093/jac/18.Supplement_B.177

10.1002/jmv.1890210208

10.1159/000057668

10.1128/JVI.79.4.2191-2198.2005

10.1007/s00705-001-0750-x

Specter R., 1988, J Pharmacol Exp Ther, 244, 516

10.2165/00003088-200241040-00003

10.1016/S0264-410X(02)00268-2

10.1073/pnas.100133697

10.1073/pnas.0506416102

10.1128/AAC.17.5.865

Reed L.J., 1938, Am J Hyg, 27, 493

Cox D.R., 1972, J R Stat Soc B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x

10.1093/jac/dki018

10.1136/bmj.302.6774.425

Sweeny D.J., 2000, Drug Metab Dispos, 28, 737

10.1016/S0166-3542(97)00061-2

Thông tin
Thông tin xuất bản

Antiviral Therapy

Tập 12 Số 3

363-370

Thông tin tác giả